Charles Zhao

Learn More
BACKGROUND Polo-like kinases (Plks) control multiple steps during the cell cycle, and Plk1 is overexpressed in urothelial cancer (UC). Volasertib (BI 6727), a Plk inhibitor, has demonstrated antitumor activity in several malignancies, including UC. In this phase 2 trial, the authors investigated volasertib as a second-line treatment in advanced/metastatic(More)
In both academic and practically oriented literature as well as on the Internet, knowledge management is used much more frequently with respect to the business world, often in conjunction with "e-business" and "virtual organizations." It has been slow for higher education to adopt knowledge management. There is no doubt that higher education is both(More)
Background Dual inhibition of activated MAPK and mTOR signaling pathways may enhance the antitumor efficacy of the MEK 1/2 inhibitor pimasertib and the mTOR inhibitor temsirolimus given in combination. Methods In this phase I study, patients with refractory advanced solid tumors (NCT01378377) received once-weekly temsirolimus plus once-daily oral pimasertib(More)
  • 1